Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Ketoprofen
Drug ID BADD_D01231
Description Ketoprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with analgesic and antipyretic properties.
Indications and Usage For symptomatic treatment of acute and chronic rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, primary dysmenorrhea and mild to moderate pain associated with musculotendinous trauma (sprains and strains), postoperative (including dental surgery) or postpartum pain.
Marketing Status approved; vet_approved
ATC Code M01AE03; M02AA10
DrugBank ID DB01009
KEGG ID D00132
MeSH ID D007660
PubChem ID 3825
TTD Drug ID D0W9WF
NDC Product Code 51604-0011; 71574-122; 0276-0506; 43235-0010; 51927-0304; 76465-0001; 12660-0006; 38779-3039; 49452-3924; 51927-0231; 45865-485; 0276-0504; 51927-0025; 51927-0057; 68981-031; 63275-9996; 82348-102; 63187-018; 38779-0078; 0378-8200; 51552-0307; 51927-0299; 79572-019
UNII 90Y4QC304K
Synonyms Ketoprofen | Benzoylhydratropic Acid | 2-(3-Benzoylphenyl)propionic Acid | Profenid | Alrheumum | Orudis | 19,583 RP | RP, 19,583 | RP-19583 | RP 19583 | RP19583 | Alrheumat
Chemical Information
Molecular Formula C16H14O3
CAS Registry Number 22071-15-4
SMILES CC(C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
General physical health deterioration08.01.03.0180.003361%-
Shock haemorrhagic14.05.05.003; 24.06.02.0140.003361%-
Balance disorder08.01.03.081; 17.02.02.0070.002240%-
Acute coronary syndrome02.02.02.015; 24.04.04.011---
Musculoskeletal discomfort15.03.04.001---
Injection site swelling08.02.03.017; 12.07.03.0180.002240%-
Vanishing bile duct syndrome09.02.03.0030.002240%-
Rectal tenesmus07.03.03.001; 15.05.03.011---
Toxic skin eruption10.01.01.008; 12.03.01.073; 23.03.05.0030.002240%-
Vasodilation procedure25.03.01.001---
Application site discolouration08.02.01.030; 12.07.01.030; 23.03.03.023---
Hot flush08.01.03.027; 21.02.02.001; 24.03.01.0050.002240%
Libido disorder19.08.03.004; 21.03.02.006---
Decreased appetite08.01.09.028; 14.03.01.005--
Erectile dysfunction19.08.04.001; 21.03.01.007--
Ill-defined disorder08.01.03.049---
Disease recurrence08.01.03.0500.002240%-
Occult blood13.05.02.003---
Urinary tract pain20.02.03.013--
Renal impairment20.01.03.010---
Erosive oesophagitis07.04.05.0040.002240%-
Liver injury09.01.07.022; 12.01.17.0120.006721%-
Hypertransaminasaemia09.01.02.0050.004481%-
Anorectal discomfort07.03.03.003---
Intestinal steatosis07.11.01.011; 14.08.04.016---
Kounis syndrome02.02.02.020; 10.01.03.037; 24.04.04.0200.003361%-
Acute kidney injury20.01.03.0160.026884%
Drug-induced liver injury09.01.07.023; 12.03.01.0440.005601%-
Drug reaction with eosinophilia and systemic symptoms10.01.01.021; 12.03.01.064; 23.03.05.0050.006721%-
Multiple organ dysfunction syndrome08.01.03.0570.002240%
The 9th Page    First    Pre   9 10    Next   Last    Total 10 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene